Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110] (Clinical Lymphoma, Myeloma and Leukemia (2021) 21(S2) (S1–S189), (S2152265021X00122))
Irene M. Ghobrial, Paula Rodríguez-Otero, Youngil Koh, Joaquín Martínez-López, Gurdeep Parmar, Miles Prince, Hang Quach, Javier de la Rubia, Emil Hermansen, Vania Hungria, Sevgi Kalayoglu Besisik, Jin Seok Kim, Xavier Leleu, Valdas Peceliunas, Fredrik Schjesvold, Franck Dubin, Christine Devisme, Lucie Lepine, Sandrine Macé, Corina OpreaMaría Victoria Mateos
Research output: Contribution to journal › Comment/debate › peer-review
Fingerprint
Dive into the research topics of 'Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110] (Clinical Lymphoma, Myeloma and Leukemia (2021) 21(S2) (S1–S189), (S2152265021X00122))'. Together they form a unique fingerprint.